Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Committee hears wide-ranging debate over bill to create stem-cell "regulatory sandbox"
Summary
Supporters said HB 12-92 would let physicians use certain regenerative stem-cell therapies earlier than current FDA timelines and attract biotech investment; opponents and some lawmakers warned about patient protections, definitional vagueness and the risk of unproven treatments for vulnerable patients.
Sponsor testimony opened with a technical and policy history of regulatory pathways and the stated goal of HB 12-92: to create state-level authority for licensed physicians to provide certain regenerative stem-cell and tissue therapies under a New Hampshire framework while preserving informed-consent protections and manufacturing safeguards.
"This bill would provide opportunities for people to heal from stem cell and tissue therapies that currently are stalled, because of the process at the FDA," the sponsor said, describing past experience as a medical device analyst and arguing that a state "regulatory sandbox" could help…
Already have an account? Log in
Subscribe to keep reading
Unlock the rest of this article — and every article on Citizen Portal.
- Unlimited articles
- AI-powered breakdowns of topics, speakers, decisions, and budgets
- Instant alerts when your location has a new meeting
- Follow topics and more locations
- 1,000 AI Insights / month, plus AI Chat
